EGFR and non-small cell lung carcinoma: In advanced NSCLC, a lack of efficacy of immune checkpoint inhibitors in patients with EGFR‐mutant NSCLC has been demonstrated in both tyrosine kinase inhibitor (TKI)‐naïve and ‐resistant settings.27, 28